Expert Guidance on Personalizing Treatment of CLL: Overcoming the Conundrum of Multiple New Agents


  • Overview of CLL Diagnosis and Evaluation
  • Case-based Discussion in the Frontline and Relapsed/Refractory Settings
    • For each case scenario, discussion will include key considerations in management decisions
  • Promising Agents and Combinations Under Investigation


Date / Time
Event Details


Program Director
John M. Burke, MD

Associate Chair
US Oncology Hematology Research Program
Rocky Mountain Cancer Centers
Aurora, Colorado

Program Director
Nicole Lamanna, MD

Associate Attending
Leukemia Service
Director of CLL Program
Hematologic Malignancies Section
Department of Medicine
New York-Presbyterian/Columbia University Medical Center
New York, New York

Jeremy Abramson, MD

Associate Professor
Department of Medicine
Harvard Medical School
Director, Center for Lymphoma
Massachusetts General Hospital
Boston, Massachusetts

John Allan, MD

Assistant Professor of Medicine
Division of Hematology and Medical Oncology
Weill Cornell Medicine
New York, New York

Farrukh Awan, MD

Associate Professor of Internal Medicine
Director of Lymphoid Malignancies Program

Harold C. Simmons Comprehensive Cancer Center
University of Texas Southwestern Medical Center
Dallas, Texas

Jacqueline C. Barrientos, MD, MS

Associate Professor of Medicine
Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
Attending Physician
Division of Hematology/Oncology
Northwell Health System
Lake Success, New York

Matthew Davids, MD

Assistant Professor of Medicine
Department of Medical Oncology
Harvard Medical School
Associate Director, CLL Center
Dana-Farber Cancer Institute
Boston, Massachusetts

Christopher R. Flowers, MD, MS

Department Chair,
Department of Lymphoma/Myeloma
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, Texas

Brian Hill, MD

Director, Lymphoid Malignancies Program
Taussig Cancer Institute
Cleveland Clinic
Cleveland, Ohio

John Pagel, MD, PhD

Chief of Hematologic Malignancies
Swedish Cancer Institute
Seattle, Washington

Goal Statement
The goal of this activity is to improve participants’ ability to optimize patient outcomes through live workshops and resources that support a shared decision making approach between clinicians and patients and that accelerate the awareness and integration of current best practices in the treatment of chronic lymphocytic leukemia.

Target Audience
This program is intended for physicians, nurses, pharmacists, and other healthcare providers and their patients with chronic lymphocytic leukemia.

Learning Objectives 

  • Consider efficacy and safety evidence as well as patient characteristics and preferences to individualize therapeutic strategies for newly diagnosed chronic lymphocytic leukemia
  • Choose optimal treatment for relapsed/refractory chronic lymphocytic leukemia based on the available clinical data and expert recommendations
  • Plan treatment strategies that sequence targeted agents to optimize patient outcomes and quality of life
  • Evaluate promising investigational agents and novel combination regimens in chronic lymphocytic leukemia, including efficacy, unique toxicities, and other practical management considerations
  • Manage adverse events associated with treatment approaches for chronic lymphocytic leukemia to ensure treatment compliance as well as improved clinical outcomes and quality of life


Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation 

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
The maximum number of hours awarded for this activity is 1.0 contact hour.

Pharmacist Continuing Education
CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-19-020-L01-P.

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.